biointel-reports / NCT03178552.html
Umesh1608's picture
regenerate 617 pivotal dossiers
f9924b9 verified
Raw History Blame Contribute Delete
9.2 kB
<!doctype html>
<html lang="en"><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>NCT03178552 β€” A Study to Evaluate the Efficacy and Safety of Multiple Targeted Thera</title>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
<style>
*{box-sizing:border-box}
body{margin:0;padding:32px 20px 60px;background:#F8FAFC;color:#0F172A;
font:15px/1.6 Inter,ui-sans-serif,system-ui,-apple-system,sans-serif;
-webkit-font-smoothing:antialiased}
.wrap{max-width:900px;margin:0 auto}
a{color:#0D9488}
.eyebrow{font-size:.72rem;font-weight:600;letter-spacing:.09em;
text-transform:uppercase;color:#64748B;margin-bottom:6px}
h1{font-size:1.6rem;line-height:1.3;margin:0 0 10px;letter-spacing:-.02em}
.meta{color:#64748B;font-size:.92rem;margin-bottom:22px}
.meta b{color:#0F172A}
.kpis{display:grid;grid-template-columns:repeat(auto-fit,minmax(130px,1fr));
gap:10px;margin:0 0 26px}
.kpi{background:#fff;border:1px solid #E2E8F0;border-radius:12px;padding:12px 14px}
.kpi .l{font-size:.67rem;font-weight:600;letter-spacing:.07em;
text-transform:uppercase;color:#64748B}
.kpi .v{font-size:1.35rem;font-weight:700;margin-top:3px;
font-variant-numeric:tabular-nums;letter-spacing:-.01em}
.kpi .s{font-size:.71rem;color:#94A3B8;margin-top:1px}
section{background:#fff;border:1px solid #E2E8F0;border-radius:14px;
padding:18px 20px;margin-bottom:16px}
h2{font-size:1.02rem;margin:0 0 12px;letter-spacing:-.01em}
table{width:100%;border-collapse:collapse;font-size:.9rem}
td{padding:7px 0;border-bottom:1px solid #F1F5F9;vertical-align:top}
td:first-child{color:#64748B;width:38%;padding-right:14px}
tr:last-child td{border-bottom:none}
.pill{display:inline-block;font-size:.74rem;font-weight:600;padding:3px 9px;
border-radius:999px;background:#F1F5F9;color:#475569}
.pill.good{background:#ECFDF5;color:#047857}
.pill.warn{background:#FEF3C7;color:#92400E}
.pill.bad{background:#FEF2F2;color:#B91C1C}
.note{font-size:.86rem;color:#64748B;border-left:3px solid #0D9488;
padding:4px 0 4px 12px;margin:12px 0 0}
.pending{border-style:dashed;background:#FAFAF9}
footer{color:#94A3B8;font-size:.78rem;margin-top:26px;line-height:1.7}
ul{margin:6px 0 0;padding-left:18px}li{margin:3px 0}
@media(prefers-color-scheme:dark){
body{background:#0B1120;color:#E2E8F0}
.kpi,section{background:#131C2E;border-color:#263349}
td{border-color:#1E293B}.meta b{color:#E2E8F0}
.pill{background:#1E293B;color:#94A3B8}
.pending{background:#0F1726}
}
</style></head><body><div class="wrap">
<div class="eyebrow">Pivotal trial dossier Β· BioIntel</div>
<h1>A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)</h1>
<div class="meta"><b>Hoffmann-La Roche</b> Β· Ph2/Ph3 Β·
<a href="https://clinicaltrials.gov/study/NCT03178552" target="_blank" rel="noopener">NCT03178552</a>
&nbsp; <span class='pill good'>exact date</span> <span class='pill warn'>enrolment is a target</span></div>
<div class="kpis"><div class='kpi'><div class='l'>Readout due</div><div class='v'>2027-06-30</div><div class='s'>Ph2/Ph3</div></div><div class='kpi'><div class='l'>Patients</div><div class='v'>1,000</div><div class='s'>estimated</div></div><div class='kpi'><div class='l'>Sites</div><div class='v'>161</div><div class='s'>27 countries</div></div><div class='kpi'><div class='l'>Arms</div><div class='v'>11</div><div class='s'>randomized</div></div><div class='kpi'><div class='l'>Masking</div><div class='v'>None</div><div class='s'>blinding depth</div></div></div>
<section><h2>Design</h2><table><tr><td>Allocation</td><td>Randomized</td></tr><tr><td>Masking</td><td>None</td></tr><tr><td>Primary purpose</td><td>Treatment</td></tr><tr><td>Arms</td><td>11</td></tr><tr><td>Planned duration</td><td>117 months</td></tr><tr><td>Started</td><td>2017-09-22</td></tr></table></section>
<section><h2>What is being measured</h2><table><tr><td>Endpoint class</td><td><span class='pill '>survival</span></td></tr><tr><td>Primary outcomes</td><td>7</td></tr><tr><td>Stated as</td><td><i>Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1 | Cohort</i></td></tr></table>
<div class="note">Endpoint class is inferred from the sponsor's own wording of
the primary outcome. Hard endpoints such as survival are generally harder to
hit than scales or laboratory surrogates.</div></section>
<section><h2>Population</h2><table><tr><td>Condition</td><td>Non-Small Cell Lung Cancer</td></tr><tr><td>Therapeutic area</td><td><span class='pill '>oncology</span></td></tr><tr><td>Patient pre-selection</td><td><span class='pill '>all-comers (no selection detected)</span></td></tr><tr><td>Modality</td><td>cell_therapy</td></tr><tr><td>Sex</td><td>ALL</td></tr></table></section>
<section><h2>Evidence trail</h2><table><tr><td>Linked references</td><td>4 on the registry record</td></tr><tr><td>Results posted</td><td><span class='pill '>not yet</span></td></tr><tr><td>Stopped early</td><td><span class='pill good'>no</span></td></tr></table></section>
<section>
<h2>Reference-class base rate</h2>
<div style="font-size:2.3rem;font-weight:700;letter-spacing:-.02em;margin:2px 0 2px">34%</div>
<div style="color:#64748B;font-size:.88rem;margin-bottom:14px">
historical share of Phase&nbsp;3 trials in this class that reached approval</div>
<div class="note"><b>This is a base rate, not a prediction about this trial.</b>
It is what happened to comparable trials historically. It is not a model
fitted on outcomes β€” no outcome labels exist for trials that have not read
out β€” and it uses none of this trial's own results.</div>
<h2 style="margin-top:18px">How this number was reached</h2>
<ol style="font-size:.9rem;padding-left:20px"><li>Published Phase 3 β†’ approval rate for oncology: 35.5% (Wong/Siah/Lo 2019) and 43.9% (BIO/Informa 2011–2020).</li><li>No biomarker selection detected. Oncology all-comer rate 33.6% replaces the band (biomarker-selected trials reach 63.6%).</li></ol>
<h2 style="margin-top:18px">Design flags</h2>
<ul style="font-size:.9rem;padding-left:20px;list-style:none"><li><span class='pill warn'>β€’</span> Runs in 27 countries. Multi-country trials show higher termination odds (OR 0.65).</li></ul>
<div class="note">Flags are shown separately rather than folded into the
number. Wood et al. (BMJ 2008) measured effect-size inflation, not approval
probability, so multiplying it into an approval rate would misuse the
finding.</div>
<h2 style="margin-top:18px">Deliberately not adjusted for</h2>
<table><tr><td>Enrollment size</td><td>no evidenced association with Phase 3 success</td></tr><tr><td>Number of sites</td><td>no evidenced association</td></tr><tr><td>Endpoint type</td><td>no evidenced association with success once area is held</td></tr><tr><td>Phase 2 design</td><td>single-arm vs randomised Phase 2 does not predict Phase 3</td></tr></table>
<div class="note">Each of these is visible in the registry and each is
evidenced to be <b>null</b> for Phase&nbsp;3 success. Using them would add
false precision.</div>
<h2 style="margin-top:18px">Evidenced, but not in the registry</h2>
<table><tr><td>Sponsor approval track record</td><td>51%β†’81% (Danzon 2005) β€” not a registry field</td></tr><tr><td>Orphan designation</td><td>aOR 2.3 β€” zero CT.gov fields carry FDA designations</td></tr><tr><td>Phase 2 effect-size shrinkage</td><td>rHR 0.73 β€” requires prior-trial results</td></tr></table>
<div class="note"><b>The standing criticism, stated plainly.</b> Hampson et al.
(<i>Pharmaceutical Statistics</i> 2022;21(2):439–459, eight of nine authors at
Novartis) argue that starting from industry rates and applying subjective
adjustments "lacks transparency and fails to make full use of data from
previous clinical trials". That criticism applies to this figure. The response
here is to show every input and to refuse unsupported adjustments, not to
claim the objection does not apply.</div>
<div style="font-size:.78rem;color:#94A3B8;margin-top:12px">
Rates: Wong, Siah &amp; Lo, <i>Biostatistics</i> 2019 (CC BY 4.0; corrigendum
values) and BIO/Informa/QLS <i>Clinical Development Success Rates 2011–2020</i>
(cited, not reproduced). MIT Project ALPHA is <b>not</b> used β€” its terms
restrict use to governmental, charitable or social purposes and bar
redistribution.</div>
</section>
<footer>
Generated 19 Oct 2026 22:33 UTC by BioIntel from public sources.
Trial data courtesy of the U.S. National Library of Medicine
(ClinicalTrials.gov API v2), <b>modified</b>: therapeutic area, endpoint class
and patient pre-selection are <b>inferred by this project</b> and are not
registry fields. NLM does not endorse this reuse. SEC filings are public domain.
<br><b>An information tool built on public filings. Not investment advice.</b>
</footer></div></body></html>